Deadline: 22-Jun-2026
The Clinical Cancer Research Grant Program is inviting applications to support innovative, patient-centered interventional clinical trials that improve cancer treatment options and quality of life. The program funds phase I to phase III clinical trials and generally offers up to USD 100,000 per year for up to five years, with a focus on therapy optimization, reducing treatment burden, and early detection or intervention.
About the Program
The Clinical Cancer Research Grant Program supports patient-focused interventional clinical trials in cancer research.
The goal is to advance clinical studies that can directly improve outcomes for patients by:
- Optimizing cancer therapies
- Reducing disease and treatment burden
- Supporting earlier detection and intervention
- Improving quality of life during and after treatment
The programme is specifically intended for interventional clinical trials and does not support basic or purely observational research.
What the Program Supports
This grant supports phase I to phase III interventional clinical trials.
Eligible studies may include:
- Early-stage to late-stage interventional clinical trials
- Trials with secondary non-clinical endpoints
- Projects that include patient partner involvement in research design
The program places strong importance on patient-centered research, meaning applicants should clearly show how patients are involved and how the trial addresses real patient needs.
Funding Information
The foundation generally provides:
- Up to USD 100,000 per year
- Maximum duration of 5 years
- Total potential support of up to USD 500,000 over the full project period
Important Funding Conditions
- Funds are disbursed based on milestone achievements
- The grant does not cover the full cost of the clinical trial
- Funding is intended primarily for non-reimbursable patient care expenses
Eligible Use of Funds
Grant funds may be used for:
- Patient participation costs
- Travel expenses
- Specialized studies
- Research supplies
- Partial salary support for key personnel
- Equipment costs, but only when directly related to the funded project
This means applicants should present a realistic budget focused on the specific trial components that are hardest to fund elsewhere.
Research Scope and Trial Requirements
The programme is open to a broad range of interventional trial designs, but certain boundaries apply.
Pharmaceutical Agents
Studies may use:
- Generic drugs
- Drugs already registered for the proposed indication
- Agents under development by academic institutions
Limited Exception
- On-patent repurposing may be considered only in rare cancer cases where no treatment options exist
What is Not Supported?
The program does not support:
- Basic research
- Observational studies
- Epidemiological studies
- Projects likely to generate revenue for start-ups
- Projects likely to generate revenue for pharmaceutical companies
This makes the grant best suited for academically driven, non-commercial clinical research with direct patient benefit.
Eligibility Criteria
Applicants must meet the following requirements:
- Hold a doctoral degree
- Have a faculty appointment or equivalent at an academic or research institution at the time of award
- Be an independent investigator
- Demonstrate the experience and training needed to:
- Design clinical trials
- Manage and implement trials
- Protect participant safety
- Maintain ethical and regulatory standards
Institutional Requirements
The host institution must:
- Show clear commitment to the applicant
- Support the proposed research
- Provide an appropriate environment for clinical trial implementation
Who Can Apply?
The programme is open to:
- Early-career researchers
- Established investigators
- International applicants and teams
There are:
- No geographical restrictions
- No cancer type restrictions
However:
- Typically, only one active grant per grantee is allowed at a time
Why This Opportunity Matters
This is a strong opportunity for clinical cancer researchers because it supports:
- Patient-centered trial design
- Phase I–III interventional studies
- Clinical questions that may not attract commercial funding
- Practical trial expenses often difficult to cover
- International and cross-institutional collaboration
It is especially valuable for investigators working on academically led clinical trials that can improve patient care but may not have direct industry backing.
Tips for a Strong Application
To improve your chances, make sure your proposal clearly shows:
- A well-defined interventional clinical trial design
- Strong patient-centered rationale
- Clear patient partner involvement
- Why the study could improve treatment options or quality of life
- A realistic milestone-based plan
- A budget focused on non-reimbursable patient care costs
- Strong investigator and institutional capacity to deliver the trial safely
Common Mistakes to Avoid
Avoid these common issues:
- Submitting basic, observational, or epidemiological research
- Proposing a project with a clear commercial revenue pathway for a start-up or pharma company
- Failing to include patient partner involvement
- Requesting the grant as if it will cover the entire trial cost
- Including equipment not clearly tied to the funded project
- Not demonstrating independent clinical trial leadership capacity
Frequently Asked Questions (FAQs)
1. What kind of research does the Clinical Cancer Research Grant Program support?
It supports phase I to phase III interventional clinical trials focused on improving cancer treatment, reducing treatment burden, and enhancing quality of life.
2. How much funding is available?
The program generally provides up to USD 100,000 per year for up to five years.
3. Does the grant cover the full cost of a clinical trial?
No. The funding is not intended to cover full trial costs. It mainly supports non-reimbursable patient care and trial-related expenses.
4. Are international researchers eligible?
Yes. There are no geographical restrictions, and international teams are welcome.
5. Are all cancer types eligible?
Yes. There are no cancer type restrictions.
6. Are observational or epidemiological studies eligible?
No. The program does not support observational, epidemiological, or basic research.
7. Can early-career investigators apply?
Yes. Both early-career and established researchers are eligible, provided they meet the independence and institutional requirements.
Final Takeaway
The Clinical Cancer Research Grant Program is a valuable funding opportunity for independent clinical researchers conducting patient-centered interventional cancer trials. With support of up to USD 100,000 per year for five years, it is especially useful for studies focused on therapy optimization, reducing treatment burden, and improving quality of life, particularly where funding is needed for patient care costs and milestone-based trial implementation.
For more information, visit RTFCCR.
